Tislelizumab or Tislelizumab Combined With Lenvatinib Neo-adjuvant Treatment for Resectable RHCC

This study is testing whether immune therapy drugs (tislelizumab alone or combined with lenvatinib) given before surgery can help people with recurring liver cancer (hepatocellular carcinoma) that can still be surgically removed. The goal is to shrink the tumor before surgery and potentially improve long-term outcomes. **You may be eligible if...** - You have been diagnosed with recurrent liver cancer after a prior curative treatment - Your cancer is still considered surgically removable by your medical team - You have at least one measurable tumor lesion and have not received local treatment for it - You are in good enough health (ECOG 0–1, Child-Pugh score 5–7) - Your organ function is adequate **You may NOT be eligible if...** - Your cancer has spread outside the liver - You have previously received immunotherapy, chemoembolization, or systemic liver cancer treatments (except curative ablation) - You have a history of autoimmune disease or active stomach/esophageal bleeding - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.